To address this question, we utilised αIR-3, a monoclonal antibody targeted against IGF-IR that has previously been shown to disrupt IGF-IR signalling and inhibit growth of some breast cancer cells both in vitro and in vivo (Arteaga, 1992). This evidence concerns the gene IGF1R and breast carcinoma.